A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients with Stages IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 11 Mar 2016 Planned End Date changed to 1 Jun 2016 as reported by ClinicalTrials.gov.
- 11 Mar 2016 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.